Search bioRxiv⌕ Search

Biology subjects

Hanlon, M. B.

Publications and source records attributed to Hanlon, M. B..

2 recordsLinked to original sources

Fully Modified SpyCas9 Guide RNAs Enable Robust Genome Editing In Cells and In Vivo

Precision engineering of CRISPR/Cas9 components has advanced genome editing toward therapeutic applications. Completely chemically stabilized guide RNAs (gRNAs) have the potential to improve in vivo editing efficacy while enabling greater flexibility in delivery strategies. However, previous generations of fully modified guides have been associated with reduced Cas9 activity. Here, we employed an iterative, structure-guided optimization strategy to systematically introduce chemical modifications at each position of SpyCas9 gRNAs. Extending beyond commonly used nucleotide modifications, we incorporated 2-amino-RNA, 4-thio-RNA, and extended nucleic acid (exNA) to generate gRNA designs in which 90-100% of the nucleotides are sugar- or backbone-modified. Although certain modification patterns exhibit sequence-dependent variability, we have established a growing repertoire of guides that consistently maintain or enhance editing efficacy when applied both in vitro and in vivo. Collectively, our heavily and fully modified gRNAs hold potential for applications in nuclease editing, base editing, and other genome editing tools. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=132 SRC="FIGDIR/small/725424v1_ufig1.gif" ALT="Figure 1"> View larger version (23K): org.highwire.dtl.DTLVardef@1118f08org.highwire.dtl.DTLVardef@1c57069org.highwire.dtl.DTLVardef@1572148org.highwire.dtl.DTLVardef@14a111e_HPS_FORMAT_FIGEXP M_FIG C_FIG

biochemistry↗

Systemic delivery of CRISPR-Cas9 nickase suppresses oncogene amplified cancer progression

Oncogene amplification is a key driver of tumorigenesis and a perpetuator of genomic instability. Oncogene amplification accelerates cancer cell proliferation and evolution, contributing substantially to the enhancement of adaptation mechanisms, such as treatment resistance, which pose a significant therapeutic challenge. However, previous studies have shown oncogene amplification to be a critical vulnerability, rendering cancer cells, but not normal cells, susceptible to targeted, CRISPR-Cas9 nickase - mediated DNA damage and cell death in vitro. Here, we demonstrate the initial framework for the translation of this potential therapeutic approach utilizing Cas9D10A - mRNA and functionalized lipid nanoparticles for the targeted delivery, and suppression of disseminated MYCN-amplified neuroblastoma in vivo.

cancer biology↗